These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 8016763)

  • 1. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
    Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
    Research Committee of the British Thoracic Society
    Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment.
    Eur Respir J; 2003 Mar; 21(3):478-82. PubMed ID: 12662005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
    Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
    Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment.
    Jenkins PA; Campbell IA;
    Respir Med; 2003 Apr; 97(4):439-44. PubMed ID: 12693807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis.
    Al Jarad N; Demertzis P; Jones DJ; Barnes NC; Rudd RM; Gaya H; Wedzicha JA; Hughes DT; Empey DW
    Thorax; 1996 Feb; 51(2):137-9. PubMed ID: 8711643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acquired rifampicin resistance during M. kansasii infection in a patient with AIDS].
    Dautzenberg B; Antoun F; Truffot C
    Rev Mal Respir; 1992; 9(4):464-6. PubMed ID: 1509191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response.
    Banks J; Hunter AM; Campbell IA; Jenkins PA; Smith AP
    Thorax; 1983 Apr; 38(4):271-4. PubMed ID: 6867979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two cases of pulmonary infection by Mycobacterium abscessus in which drug susceptibility testing results conflicted with clinical courses].
    Nishizawa Y; Fujimura M; Tagami A; Abo M; Honjyo C; Yasui M; Nakao S
    Nihon Kokyuki Gakkai Zasshi; 2005 Apr; 43(4):241-6. PubMed ID: 15966372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):628-34. PubMed ID: 12102303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
    Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
    J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampin-resistant Mycobacterium kansasii.
    Wallace RJ; Dunbar D; Brown BA; Onyi G; Dunlap R; Ahn CH; Murphy DT
    Clin Infect Dis; 1994 May; 18(5):736-43. PubMed ID: 8075262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
    Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
    Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs.
    Ahn CH; Lowell JR; Ahn SS; Ahn S; Hurst GA
    Rev Infect Dis; 1981; 3(5):1028-34. PubMed ID: 7339800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients.
    Rooney G; Nelson MR; Gazzard B
    J Clin Pathol; 1996 Oct; 49(10):821-3. PubMed ID: 8943748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
    Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
    Sauret J; Hernández-Flix S; Castro E; Hernández L; Ausina V; Coll P
    Tuber Lung Dis; 1995 Apr; 76(2):104-8. PubMed ID: 7780090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary disease caused by Mycobacterium terrae complex.
    Tonner JA; Hammond MD
    South Med J; 1989 Oct; 82(10):1279-82. PubMed ID: 2678502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].
    Wagner D; Lange C
    Pneumologie; 2020 Nov; 74(11):773-779. PubMed ID: 33202438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.